KPV

Overview

KPV (Lysine-Proline-Valine) is the three-amino-acid tail of alpha-melanocyte-stimulating hormone (alpha-MSH). Researchers isolated this fragment because it appears to carry much of the parent hormone's anti-inflammatory activity while leaving behind the part of the molecule responsible for stimulating skin pigment. In practical terms it is studied as a small, targeted anti-inflammatory rather than as a tanning or melanotan-type peptide.

Evidence Quality

The evidence base for KPV is almost entirely preclinical. Multiple cell-culture and rodent studies published in respected journals show clear anti-inflammatory effects, but there are no large, controlled human trials establishing efficacy or long-term safety. For that reason it is best regarded as an early-stage research compound, and any human use is anecdotal and off-label. On a simple A-D scale this lands around a C: mechanistically well-described and promising, but unproven in people.

What the Research Shows

In laboratory models KPV reduces inflammation by interfering with core inflammatory signaling pathways, including NF-kB and MAP-kinase, which lowers the production of pro-inflammatory cytokines. A key finding is that inflamed intestinal tissue takes KPV up directly through the PepT1 peptide transporter, which is switched on in the colon during inflammatory bowel disease. In mouse models of colitis, oral KPV reduced inflammation, improved weight recovery, and lowered inflammatory markers, and it remained effective even when the melanocortin-1 receptor was non-functional, suggesting more than one mechanism is at work. Later work packaged KPV into orally delivered nanoparticles that further improved its delivery to the inflamed colon.

Dosage Notes

There is no established clinical dose. In the research and community setting KPV is typically used at roughly 200-500 mcg per day. It is taken two ways: subcutaneous injection for a systemic, whole-body anti-inflammatory effect, and orally (as capsules or a reconstituted liquid) when the goal is to act on gut inflammation directly. Users commonly run it in blocks of about 4-8 weeks and then reassess, and it is frequently paired with BPC-157 in gut-healing protocols.

Who Should Be Cautious

Because human data are essentially absent, anyone with a diagnosed medical condition, especially inflammatory bowel disease or another serious inflammatory or immune disorder, should not use KPV as a substitute for evidence-based treatment and should involve a qualified clinician. Pregnant or breastfeeding individuals and anyone on immune-modulating medication should avoid it. Product quality varies widely between vendors, so third-party testing matters.

Availability

KPV is sold as a research chemical, not as an approved medicine. It is commonly offered as lyophilized powder in multi-milligram vials (for example 5 mg and 10 mg vials in 3 mL glass) that the user reconstitutes with bacteriostatic water, and increasingly as oral capsules. It is not FDA-approved, and vendors label it for research use only.

Bottom Line

KPV is a well-characterized anti-inflammatory fragment of alpha-MSH with genuinely interesting preclinical data, particularly for gut inflammation, and without the tanning effect of related melanocortin peptides. What it lacks is human trial evidence, so it remains an experimental, research-only compound rather than a proven therapy.